vimarsana.com

Page 4 - ஆராய்ச்சி க்கு ப்ரெவெந்ஶந் மாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IAS Home

Founded in 1988, the International AIDS Society (IAS) is the world’s largest association of HIV professionals, with members from more than 180 countries working on all fronts of the global AIDS response. The IAS is also the steward of the world’s two most prestigious HIV conferences – the International AIDS Conference and the IAS Conference on HIV Science.

African nations lead the world in offering PrEP HIV prevention drug

Daniel Born/The Times/Gallo Images/Getty Images Nearly 1 million people are now taking pre-exposure prophylaxis (PrEP), medicine that can slash the risk of HIV infections. While early use of the drug was mostly limited to Western nations, the number of users in sub-Saharan Africa (SSA) has now drastically increased, accounting for more than half of the world’s PrEP users. Kate Segal at AVAC, a New York-based non-profit focused on global HIV prevention, presented the latest data on PrEP use at the virtual HIV Research for Prevention Conference on 26 January. She said there had been a major expansion of PrEP users in 2020, with a rise of more than 300,000 from the previous year. In SSA, expanded access saw the number of new users jump from 4154 in 2016 to more than 517,000 in 2020, representing 56 per cent of the global total.

New ethical obligations for researchers in places where existing HIV prevention services are inadequate

Peter Godfrey-Faussett (top right) presenting at HIVR4P 2021. A full package of effective prevention interventions, up to international standards, must be offered to people taking part in HIV prevention trials, say UNAIDS and WHO in new guidance issued this week. This means that if researchers want to run a study in a country in which PrEP is not routinely available, they must find a way to provide it to study participants. If the study demonstrates that a new product is effective, the researchers have new obligations to provide it to study participants at the end of the trial and help make it available to the wider population.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.